JP2010501022A - βアゴニストの吸入用エアロゾル製剤 - Google Patents

βアゴニストの吸入用エアロゾル製剤 Download PDF

Info

Publication number
JP2010501022A
JP2010501022A JP2009525030A JP2009525030A JP2010501022A JP 2010501022 A JP2010501022 A JP 2010501022A JP 2009525030 A JP2009525030 A JP 2009525030A JP 2009525030 A JP2009525030 A JP 2009525030A JP 2010501022 A JP2010501022 A JP 2010501022A
Authority
JP
Japan
Prior art keywords
acid
enantiomers
drug formulation
hydroxy
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009525030A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010501022A5 (und
Inventor
キルシュテン ラダウ
ミハエル アーフェン
ライナー ヴァイツェル
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2010501022A publication Critical patent/JP2010501022A/ja
Publication of JP2010501022A5 publication Critical patent/JP2010501022A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2009525030A 2006-08-18 2007-08-16 βアゴニストの吸入用エアロゾル製剤 Pending JP2010501022A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06119131 2006-08-18
EP07101129 2007-01-25
PCT/EP2007/058518 WO2008020057A1 (de) 2006-08-18 2007-08-16 Aerosolformulierung für die inhalation von betaagonisten

Publications (2)

Publication Number Publication Date
JP2010501022A true JP2010501022A (ja) 2010-01-14
JP2010501022A5 JP2010501022A5 (und) 2010-10-07

Family

ID=38521160

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009525030A Pending JP2010501022A (ja) 2006-08-18 2007-08-16 βアゴニストの吸入用エアロゾル製剤

Country Status (18)

Country Link
US (2) US20080041369A1 (und)
EP (1) EP2054084A1 (und)
JP (1) JP2010501022A (und)
KR (1) KR20090057393A (und)
AR (1) AR062425A1 (und)
AU (1) AU2007285747A1 (und)
BR (1) BRPI0715761A2 (und)
CA (1) CA2660488A1 (und)
CO (1) CO6170341A2 (und)
IL (1) IL197025A0 (und)
MX (1) MX2009001759A (und)
NO (1) NO20090407L (und)
NZ (1) NZ575425A (und)
PE (1) PE20081319A1 (und)
SG (1) SG174058A1 (und)
TW (1) TW200817011A (und)
UY (1) UY30542A1 (und)
WO (1) WO2008020057A1 (und)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US20050255050A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Powder formulations for inhalation, comprising enantiomerically pure beta agonists
US7220742B2 (en) * 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
AU2006281449B2 (en) * 2005-08-15 2013-01-31 Boehringer Ingelheim International Gmbh Method for producing betamimetics
EP2675439A2 (en) 2011-02-17 2013-12-25 Cipla Limited Combination of glycopyrrolate and a beta2 -agonist
EP3318247A1 (en) 2011-08-12 2018-05-09 Boehringer Ingelheim Vetmedica GmbH Taste masked pharmaceutical composition
WO2014016548A2 (en) 2012-07-27 2014-01-30 Cipla Limited Pharmaceutical composition
CA2888428C (en) 2012-12-21 2021-07-13 Boehringer Ingelheim Vetmedica Gmbh Ciclesonide for the treatment of airway disease in horses
WO2014096116A1 (en) * 2012-12-21 2014-06-26 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical formulation comprising ciclesonide
CA2952701C (en) 2014-06-18 2023-09-19 Boehringer Ingelheim Vetmedica Gmbh Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses
US11701478B2 (en) 2015-10-09 2023-07-18 Boehringer Ingelheim International Gmbh Method for coating microstructured components
CN115811978B (zh) * 2020-06-23 2024-04-26 广州谷森制药有限公司 包含奥达特罗、噻托溴铵和布地奈德的药物组合物的制备

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502608A (ja) * 2001-06-23 2005-01-27 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 抗コリン作用剤とコルチコステロイドとβ刺激剤を含む新規な医薬組成物
WO2005102349A1 (de) * 2004-04-22 2005-11-03 Boehringer Ingelheim International Gmbh Arzneinmittelkombinationen enthaltend benzoxazine zur behandlung von atemwegserkrankungen
WO2005111005A1 (de) * 2004-05-14 2005-11-24 Boehringer Ingelheim International Gmbh Neue enantiomerenreine betaagonisten, verfahren zu deren herstellung und deren verwendung als arzneimittel
JP2006508140A (ja) * 2002-11-15 2006-03-09 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 慢性閉塞性肺疾患を治療するための新規医薬

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR890000664B1 (ko) * 1981-10-19 1989-03-22 바리 안소니 뉴우샘 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
DE102004019540A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen
US20050239778A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim International Gmbh Novel medicament combinations for the treatment of respiratory diseases
US7220742B2 (en) * 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US7528253B2 (en) * 2004-08-16 2009-05-05 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502608A (ja) * 2001-06-23 2005-01-27 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 抗コリン作用剤とコルチコステロイドとβ刺激剤を含む新規な医薬組成物
JP2006508140A (ja) * 2002-11-15 2006-03-09 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 慢性閉塞性肺疾患を治療するための新規医薬
WO2005102349A1 (de) * 2004-04-22 2005-11-03 Boehringer Ingelheim International Gmbh Arzneinmittelkombinationen enthaltend benzoxazine zur behandlung von atemwegserkrankungen
WO2005111005A1 (de) * 2004-05-14 2005-11-24 Boehringer Ingelheim International Gmbh Neue enantiomerenreine betaagonisten, verfahren zu deren herstellung und deren verwendung als arzneimittel

Also Published As

Publication number Publication date
PE20081319A1 (es) 2008-10-16
SG174058A1 (en) 2011-09-29
US20080041369A1 (en) 2008-02-21
US20120058980A1 (en) 2012-03-08
NO20090407L (no) 2009-04-29
MX2009001759A (es) 2009-02-25
UY30542A1 (es) 2008-03-31
CA2660488A1 (en) 2008-02-21
AR062425A1 (es) 2008-11-05
WO2008020057A1 (de) 2008-02-21
NZ575425A (en) 2011-12-22
BRPI0715761A2 (pt) 2013-09-24
TW200817011A (en) 2008-04-16
IL197025A0 (en) 2009-11-18
CO6170341A2 (es) 2010-06-18
AU2007285747A1 (en) 2008-02-21
EP2054084A1 (de) 2009-05-06
KR20090057393A (ko) 2009-06-05

Similar Documents

Publication Publication Date Title
JP2010501021A (ja) βアゴニストの吸入用エアロゾル製剤
JP2010501022A (ja) βアゴニストの吸入用エアロゾル製剤
TWI389692B (zh) 用以吸入β-共效劑的氣溶膠調配物
JP2009514933A (ja) 吸入用エアロゾル製剤
US20110281858A1 (en) Aerosol formulation for the inhalation of beta agonists
US20110319402A1 (en) Aerosol formulation for the inhalation of beta agonists
CN101505798A (zh) 吸入用β-激动剂的气雾剂
US20060153777A1 (en) Aerosol formulation for inhalation containing an anticholinergic
CN101505728A (zh) 含β-激动剂和类固醇的气雾剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121029

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130408